➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Express Scripts
Harvard Business School
Dow
Medtronic

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PALONOSETRON HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Palonosetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00306735 ↗ Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Helsinn Healthcare SA Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00306735 ↗ Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Eisai Inc. Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00343460 ↗ APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Completed Heron Therapeutics Phase 3 2006-04-01 RATIONALE: Antiemetic drugs, such as APF530, palonosetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for cancer. It is not yet known whether APF530 is more effective than palonosetron when given together with dexamethasone in preventing nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
NCT00343863 ↗ Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed National Cancer Institute (NCI) N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
NCT00343863 ↗ Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed University of Washington N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Palonosetron Hydrochloride

Condition Name

Condition Name for Palonosetron Hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 27
Postoperative Nausea and Vomiting 16
Nausea 10
Vomiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Palonosetron Hydrochloride
Intervention Trials
Vomiting 81
Nausea 68
Postoperative Nausea and Vomiting 22
Breast Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Palonosetron Hydrochloride

Trials by Country

Trials by Country for Palonosetron Hydrochloride
Location Trials
United States 221
China 24
Italy 21
Korea, Republic of 16
Brazil 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Palonosetron Hydrochloride
Location Trials
Texas 15
Ohio 13
Florida 12
California 11
New York 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Palonosetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 29
Phase 2/Phase 3 3
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Completed 52
Recruiting 26
Not yet recruiting 16
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Palonosetron Hydrochloride

Sponsor Name

Sponsor Name for Palonosetron Hydrochloride
Sponsor Trials
Helsinn Healthcare SA 15
Eisai Inc. 11
National Cancer Institute (NCI) 9
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Palonosetron Hydrochloride
Sponsor Trials
Other 121
Industry 51
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Dow
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.